MedPath

Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke: A multicenter, randomized, open-label phase II trial.

Completed
Conditions
Stroke, transient ischemic attack, impaired glucose tolerance.Herseninfarct, TIA, gestoorde glucose tolerantie.
Registration Number
NL-OMON25556
Lead Sponsor
Erasmus Medical Center
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1. 18 years or older;

2. Clinical diagnosis of TIA, amaurosis fugax or minor ischemic stroke within the previous 6 months;

Exclusion Criteria

1. Diabetes mellitus;

2. History of diabetic ketoacidosis;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Baseline adjusted difference in 2-hour post-load glucose levels at 6 months
Secondary Outcome Measures
NameTimeMethod
1.Baseline adjusted difference in fasting glucose levels at 6 months<br>2.Baseline adjusted difference in glycosylated hemoglobin 1c (HbA1c) levels at 6 months<br>3.Tolerability of metformin and sitagliptin assessed as number of patients still on treatment after 6 months;<br>4.Safety of treatment with metformin and sitagliptin assessed as percentage of (serious) adverse events in the treatment groups at 6 months;<br>5.Percentage of patien2ts with a normal glucose tolerance at 6 months.
© Copyright 2025. All Rights Reserved by MedPath